Norwalk, CT, May 25, 2018 – Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.

“Now in its 7th year, Life Science Leader’s CMO Leadership Awards provide readers with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.” LSL

Norwalk, CT, March 30, 2018 -- Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that the acquisition of the GlaxoSmithKline (GSK) manufacturing facility in Aiken, South Carolina (USA) is complete.

Norwalk, CT. October 11, 2017.

Avara Pharmaceutical Services is a world-class contract development and manufacturing organization (CDMO) with an extensive network of operations serving the global bio- pharmaceutical market

Avara Pharmaceutical Services is a world class contract development and manufacturing organization (CDMO) with an extensive network serving the global bio-pharmaceutical market

Avara Pharmaceutical Services has signed an agreement with GSK to acquire a GSK Secondary Manufacturing and Packaging facility in Aiken, South Carolina. "This acquisition is an important component of our strategic plan and expands our services by adding additional solid dose capability in the United States, which is in very high demand," stated Timothy C. Tyson, Chairman and CEO. The transaction is expected to complete on or before June 1, 2018.

Avara Pharmaceutical Services is a world class contract development and manufacturing organization (CDMO) with an extensive network serving the global bio-pharmaceutical market

Norwalk, CT, August 2017 -- Avara Pharmaceutical Services has signed an agreement with Pfizer Inc. to acquire the Liscate, Italy sterile manufacturing facility. “This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand”, stated Timothy C. Tyson, Chairman and CEO.

 
Created in 2015, Avara Pharmaceutical Services is a state-of-the-art contract development and manufacturing organization (CDMO) providing both primary formulation and manufacturing, and secondary manufacturing and packaging of small molecules.

Norwalk, CT, September 6, 2016 - Avara Pharmaceutical Services, Inc. (“Avara”) today announced that they have entered into an agreement under which Avara will acquire AstraZeneca’s manufacturing facility located in Avlon, Avonmouth, England.

Norwalk, CT, August 3rd, 2016 –Avara Pharmaceutical Services, Inc. announced that its subsidiary, Avara Norman Pharmaceutical Services, Inc. (“Avara”) entered into an agreement under which Avara will acquire Astellas’s wholly owned manufacturing subsidiary Astellas Pharma Technologies (APT), Inc., located in Norman, Oklahoma.